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Purification and characterization of 21 ckymotrypsin Kurriik; iiilaitjiitir type 
of polypeptide from the venom of cobra (Nqb wju H@~) 
A chynr:Itrypsin Kunitz inhibitor type of polppcptidc bus been isolated form the VL’IIOI~ of h’trjtr UCQ~~ r~trjrl try revsrse ph;~ss I II’LC ilIlt Wion “A- 
clli\ngc FPtC. It is prcscnt in ;I co~~sidorubly lorwr utmunt thnn th;~t of the corresponding trypsin inhibitor. The primury structlrrc. tlctcrininctl 
by scqucn~c :tn;llysis ol’thc wllolr molecule und its tryptic pcptidcs, hus 57 rcsiducs with in ~ippnrsnt molcsulnr nUSs of 6.2 kUii. The ~tthtt cot~t;i~t 
site with the protcnsc (PI) has;, Phc, showing the specificity of the inhibitor, Of rcsidurs consitlcrcd futlctic)n;llly imporlunt in Kunitz-type inhibitws. 
Oly-36 is rcplttcsd by Scr in ;L scymcn~ of wcitk ContilCts with the pr~>tcilsC. 
Siukc ~cnom: Cobra; HI’LC-I’PLC scpirr;ltir>n; Kunitx.type chymotrypsin inhibitor; iunino acid scqucr~c: Weak colltxt silo rcplaccmcnt 
1, INTRODUCTION 
The presence of Kunitz-type serinc protcasc in- 
hibitors in the venoms of Elapidae and Viperidae 
snakes is well-known [l] and several of these inhibitors 
have been characterized [Z-6], They are non-toxic, 
basic golypeptides. Their actual role in the venom has 
not been directly established, but their, inhibitory pro- 
perties on regulatory mechanisms in tissues, influencing 
the proteases of coagulation, fibrinolysis and inflam- 
mation, have of course been considered. In a few cases, 
the inhibitors have been observed to give a synergistic 
increase in the toxicity of some toxins [9]. During our 
investigation of components of the venom from Naja 
nJa naja (Pakistan), we have reported on the presence 
of a highly potent, Kunitz-type trypsin inhibitor, having 
a6i values of 3.5 x lo- l2 M [6]. WC have now also 
isolated a chymotrypsin i hibitor-like polypeptide from 
the cobra venom. Determination of its primary struc- 
ture clearly identifies it as a Kunitz-type inhibitor. 
2. MATERIALS AND METHODS 
Crude cobra venom was separated by reverse phase HPLC as 
described [6&I]. The inhibitor eluted immediately after the neurotoxin 
as a small fraction (peak Din Fig. 1 of [a]). It was purified further by 
FPLC on Mono S in 20 tnM sodium phosphate, pH 6.8, with a linear 
gradient of O-l M NaCl, and was then re-chromatographed by the 
Corrcsporrdence address; H. JBrnvall, Department of Chemistry I, 
Karolinska Institutet, S-104 01 Stockholm, Sweden 
rcversc phase HPLC step. The pure inhibitor (6 nmol) was reduced 
with dithioerythritol and curboxymcthylntcd with “CAabcllcd 
iodoncctatc [6]. Digcsiion with trypsin was carGd out in 0.1 M am- 
monium bicarbonate, pH 8.1, at 37°C for 4 11 with an cn- 
zyme/substratc ratio of l:lOO, by weight. The tcyptic pcptidcs were 
scparnted by reverse phase I-IPLC on Cl8 (Ultropak, LKB) in 0.1010 
trifluoroacetic acid wit,h a linear gradient of acetonitrilc [a]. 
Amino acids were dctermincd with a Beckman 121M analyzer oftcr 
acid hydrolysis at 110°C in 6 M HCl/O.S~lo phenol for 24 h in 
evacuated tubes. Amino acid scquenccs were annlyzcd with an Ap- 
plied Riosystems 470A gas-phuse scqucncer and a Hewlett-Packard 
HPLC for thiohydantoin idcntificotion [9] or a MilliGcn ProSc- 
qucncer 6600 solid-phase instrument utilizing arylnminc mcmbrancs 
for C-terminal attachment. The carboxymcth),lcysteinc positions 
were confirmed by monitoring the radioactivity. 
3. RESULTS 
The separation pattern of cobra (Baja naju naju) 
crude venom upon reverse phase MPLC on Vydac Cl8 
has been reported [a]. The present inhibitor cor- 
responds to one of the minor fractions (D in Fig. 1 of 
[6]), It was further purified by FPLC on Mono-S (Fig. 
1), eluting early (peak 1 in Fig. 1) and being separated 
from a contaminating neurotoxin derived from the ad- 
jacent fraction of the previous HPLC step (peak C in 
w 
The inhibitor was reduced, “C-carboxymethylated 
and analyzed. The amino acid sequence was obtained 
by solid-phase sequencer (MilliGen 6600) degradation 
of the intact molecule utilizing C-terminal attachment, 
complemented by gas-phase sequencer degradation 
(Applied Biosystems 4904 of the tryptic peptides for 
establishment of the C-terminal end and verification of 
6 
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internal regions (Fig. 2). The total composition (Table 
I) supports the structure deduced. 
The results identify the protein as a Kunitz-type pro- 
tcasc inhibitor. Thus, it is distantly homologous (58% 
residue identity) to the trypsin inhibitor in the venom of 
the same species [6], but in contrast o the latter, it has 
Phe at position 15 (Fig. 3). This is the spccificity- 
determining position, $1 of inhibitors [IO], and sug- 
gests that thr. present venom molecule is of the 
chymotrypsin inhibit,or type. it is present in much lower 
amounts than the corresponding trypsin inhibitor 
(roughly l/10, as judged from the relative peak heights 
upon purification, cf. peaks 13 and B in [6]), and ap- 
pears not to have been characterized before in Elapidae 
snakes, but is known from a Viperidae snake [l 1] and 
silkworm larvae [12]. The structures of all these 
molecules asd bovine basic pancreatic trypsin inhibitor 
1131 are compared in Fig. 3, showing the distant 
similarities, the distinguishing Pl positions of the two 
groups, the important residues in common, and the 
deviating functional residues now detected, as discussed 
below. 
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Fig. 2. Primary structure of the Ku&z-type chymotrypsin i hibitor- 
like polypeptide. Solid lines indicate peptidc parts analyzed by 
sequences degradations, broken lines remaining parts. Tl-T4 
constitute the tryptic peptides analyzed. 
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Values frown ncid hydrolysis, and, within parenthow, scqucnce 
annlysir. 
4. DISCU§§ION 
The primary structure of this novel inhibitor from 
Nsj~ rlajfl r~ff)d venom was determined. Nearly the en- 
tire structure was obtained by degradation in a solid- 
phase instrument for 50 cycles. The remaining part was 
completed by analysis crf the tryptic peptides of the 
radiolabelled S-carboxymethylated inhibitor. The 
57-residue structure has 6 Cys positions. Their pattern 
and an entire-chain residue homology identify the 
venom compoilent as a Ku&z-type inhibitor, with the 
Cys positions corresponding to the 6 invariant half- 
cystine residues of these inhibitors. Known relation- 
ships for the basic pancreatic trypsin inhibitor and 
other members within this family also allow functional 
conclusions on protease-interacting residues at critical 
positions [IO]. 
The residue corresponding to the main contact site 
(Pl) is Phe-15 (Fig. 3). The presence of residues like 
Phe, keu and Tyr at this position are supposed to be 
typical for chymotrypsin inhibitors and we therefore 
conclude that the new cobra venom component 
characterized is a chymotrypsin-type of inhibitor. Com- 
ponents with such P1 residues have been observed in the 
hemolymph of larvae of a silkworm, Bombyx mori, 
having Phe [LZ], and from the venom of Vipwe am- 
modytes, having Keu at this position (Fig. 3). Both are 
strong inhibitors towards ol-chymotrypsin, with 
dissociation constants Ki of 4.3 x IO-’ M and 1.3 x 
10 - 8 M, respectively, while similar peptidcs having Tyr 
at this position have been isolated from the venom of 
Rcsiducs at other positions tllought to bc involved in 
protcnsc binding, including tlrosc with weak interac- 
tions, like Cily-12(W), Tyr-23, Asn-24, Phc-33, Tyr-35, 
Gly-37, Asn-43, and Phe-45 [14] are iargcly conscrvcd. 
Only the residue at position 36 is different in the novel 
/Vujcr molecule, being Scr instead of an otherwise con- 
served Gly-36 (Fig. 3). Consequently, both the trypsin 
inhibitor rucently characterized from Baja PtCrjll ruja [6] 
and the chymotrypsin-type of inhibitor now detected 
from the s~:ne species, exhibit special propcrtics with 
deviating residues of functional imyorrance. In the 
former case, a different residue at P 1, probably cx- 
plaining a strong inhibitory power [6] and in thr: present 
case a deviation in an otherwise conserved residue at a 
weak contact site. 
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